Insulin-like growth factor II messenger RNA–binding protein-3 is a valuable diagnostic and prognostic marker of intraductal papillary mucinous neoplasm

Morimatsu, Katsuya; Aishima, Shinichi; Yamamoto, Hidetaka; Hayashi, Akifumi; Nakata, Kohei; Oda, Yasunori; Shindo, Koji; Fujino, Minoru; Tanaka, Masao

doi:10.1016/j.humpath.2012.12.020

Cited by 21 publications

(13 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 53 studies involved 8,937 patients with different cancer types, including 6 studies of RCC,8,25–29 6 lung cancer,9,30–34 4 oral cancer,10,35–37 4 urothelial carcinoma,38–41 4 ovarian cancer,16,17,42,43 3 hepatocellular carcinoma (HCC),44–46 4 colorectal cancer,12,47–49 3 prostate cancer,14,15,50 3 pancreatic cancer,51–53 2 gastric cancer,11,54 2 intrahepatic cholangiocarcinoma (ICC),55,56 and one study each of tongue cancer,57 thyroid carcinoma,58 sacral chordoma,59 pilocytic astrocytoma and pilomyxoid astrocytoma (PA/PMA),60 neuroblastoma,61 meningioma,62 melanoma,63 breast cancer,64 giant cell tumor,65 bile duct carcinoma,66 esophageal carcinoma,67 and cervical cancer 13. A total of 25 studies involved Caucasians and 28 involved Asians.…”

Section: Resultsmentioning

confidence: 99%

Prognostic value of high IMP3 expression in solid tumors: a meta-analysis

Chen¹,

Xie²,

Li³

et al. 2017

OTT

View full text Add to dashboard Cite

BackgroundAccumulated studies have investigated the prognostic role of insulin-like growth factor II mRNA-binding protein 3 (IMP3) in various cancers, but inconsistent and controversial results were obtained. Therefore, we performed a systematic review and meta-analysis to investigate the potential value of IMP3 in the prognostic prediction of human solid tumors.Materials and methodsA systematic literature search in the electronic databases PubMed, Embase, Web of Science, and Cochrane library (updated to April 2016) was conducted to identify eligible studies. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for survival outcomes were calculated and gathered using STATA 12.0 software.ResultsA total of 53 studies containing 8,937 patients with solid tumors were included in this meta-analysis. High IMP3 expression was significantly associated with worse overall survival (OS) of solid tumors (HR =2.08, 95% CI: 1.80–2.42, P<0.001). Similar results were observed in cancer-specific survival (CSS), disease-free survival (DFS), recurrence-free survival (RFS), progression-free survival (PFS), and metastasis-free survival (MFS). Further subgroup analysis stratified by tumor type showed that elevated IMP3 expression was associated with poor OS in renal cell carcinoma (RCC), lung cancer, oral cancer, urothelial carcinoma, hepatocellular carcinoma (HCC), colorectal cancer, pancreatic cancer, gastric cancer, and intrahepatic cholangiocarcinoma (ICC).ConclusionThe current evidence suggests that high IMP3 expression is associated with poor prognosis in most solid tumors. IMP3 is a potential valuable prognostic factor and might serve as a promising biomarker to guide clinical decisions in human solid tumors.

show abstract

Section: Resultsmentioning

confidence: 99%

Prognostic value of high IMP3 expression in solid tumors: a meta-analysis

Chen¹,

Xie²,

Li³

et al. 2017

OTT

View full text Add to dashboard Cite

show abstract

“…IMP3 is expressed in malignant neoplasms, including intraductal papillary mucinous neoplasms (27), pancreatic adenocarcinoma (28,29) and hepatocellular carcinoma (30). In these tumors, IMP3 expression is a useful diagnostic marker for distinguishing the malignant phenotype from benign lesions and is a prognostic biomarker associated with poor survival.…”

Section: Discussionmentioning

confidence: 99%

Expression of glucose transporter-1 is correlated with hypoxia-inducible factor 1α and malignant potential in pancreatic neuroendocrine tumors

et al. 2016

Self Cite

View full text Add to dashboard Cite

The present study aimed to investigate the prognostic usefulness of the expression of glucose transporter type 1 (GLUT-1) and GLUT-2, hypoxia-inducible factor 1α (HIF-1α) and insulin-like growth factor II messenger RNA-binding protein 3 (IMP3) in pancreatic neuroendocrine tumors (pNETs). Immunohistochemical staining for GLUT-1, GLUT-2, HIF-1α and IMP3 was performed in 70 pNET specimens. The expression of GLUT-1 and HIF-1α was significantly higher in the World Health Organization grade 2 (G2), neuroendocrine carcinoma cases and mixed-type pNETs compared with the G1 cases. Vessel invasion, a high Ki-67 labeling index and a high mitotic count were significantly more frequent in the GLUT-1- and HIF-1α-positive cases compared with the negative cases. Lymph node metastasis was significantly higher in the GLUT-1-positive cases than in the negative cases. Insulin expression was significantly higher in the IMP3-positive cases than the negative cases. The GLUT-1 expression group experienced a significantly poor disease-free survival rate compared with the negative GLUT-1 expression group. HIF-1α expression was significantly correlated with poor disease-free survival and overall survival rates. A multivariate analysis revealed that lymph node metastasis was an independent risk factor for disease-free survival in all cases. In the G1/G2 group, tumor size and lymph node metastasis were independent risk factors for disease-free survival. Overall, the results suggested that GLUT-1 is a useful prognostic biomarker for pNETs.

show abstract

“…In our study, HG-noninv as well as HG-inv and control HGSCs showed p16 overexpression and infrequent PAX2 expression, whereas SBTs showed frequent PAX2 expression and infrequent p16 overexpression. IMP3 is an oncofetal protein highly expressed in some kinds of malignant tumors, such as pancreatic and endometrial serous cancers [26,27]. Although IMP3 expression has been reported in ovarian cancers including serous carcinomas [28], the expression level in SBT and LGSCs has not been specifically investigated.…”

Section: Discussionmentioning

confidence: 99%

Ovarian high-grade serous carcinoma with a noninvasive growth pattern simulating a serous borderline tumor

et al. 2015

Self Cite

View full text Add to dashboard Cite

Ovarian serous borderline tumors (SBTs) being a precursor of low-grade serous carcinomas are morphologically characterized by noninvasive growth and low-grade cytology. On the other hand, many pathologists regard cytologically high-grade, noninvasive (HG-noninv) ovarian serous tumors resembling SBTs in low magnification as conventional high-grade serous carcinomas (HGSCs) by personal experiences. Nonetheless, there are no established molecular characteristic of such tumors. In this study, therefore, we attempted to provide the molecular evidence. We selected 37 ovarian serous tumors that exhibited a cytologically HG-noninv growth pattern, including 36 tumors that coexisted with conventional invasive HGSC components (HG-inv) and a single tumor exclusively composed of pure HG-noninv. Histologically, all HG-noninv showed many mitotic figures, and serous tubal intraepithelial carcinomas were identified in 3 tumors with HG-noninv. Immunohistochemically, most HG-noninv showed aberrant p53 expression, frequent IMP3 positivity, p16 overexpression, a high MIB-1 labeling index, and infrequent PAX2. By molecular analysis, the pure HG-noninv and 13 HGSCs with HG-noninv showed TP53 mutations, but KRAS/BRAF mutations were not detected in any of them. In 1 tumor, we detected an identical TP53 mutation in both HG-noninv and HG-inv components by using laser capture microdissection. These immunohistochemical and molecular features of HG-noninv were similar to those of conventional invasive HGSCs but different from those of SBTs. In conclusion, our results showed that a cytologically HG-noninv growth pattern simulating an SBT is a morphological spectrum of HGSC, but not a true SBT.

show abstract

Insulin-like growth factor II messenger RNA–binding protein-3 is a valuable diagnostic and prognostic marker of intraductal papillary mucinous neoplasm

Cited by 21 publications

References 32 publications

Prognostic value of high IMP3 expression in solid tumors: a meta-analysis

Prognostic value of high IMP3 expression in solid tumors: a meta-analysis

Expression of glucose transporter-1 is correlated with hypoxia-inducible factor 1α and malignant potential in pancreatic neuroendocrine tumors

Ovarian high-grade serous carcinoma with a noninvasive growth pattern simulating a serous borderline tumor

Contact Info

Product

Resources

About